Active Biotech AB accepts offer from Carl Bennet AB on shares in Lifco AB
The Board of Active Biotech AB has decided to accept Carl Bennet AB's public
offer on shares in Lifco AB at the price of 42 SEK per share.
The shares will be transfered in accordance with the offer.
Active Biotech's shareholding amounts to 1 812 103 Lifco serie B,
corresponding to 19,9% of the capital and 12,5% of the votes.
The stockholding is a financial asset and a capital gain of 11,0 MSEK will
arise upon sale.
Lund 2 August 2000
Active Biotech AB (publ)
President & CEO
Active Biotech AB is a Swedish biotechnology company focused on the research
and development of pharmaceuticals and vaccines, the core competence being
knowledge of the human immune system. Active Biotech has a high quality
project portfolio and considerable financial resources. Important products and
projects include Dukoral, SBLCholera Vaccine, a vaccine against tourist
diarrhoea (ETEC), innovative drugs against MS (SAIK) and cancer (TTS). The
turnover of Active Biotech was SEK 267 million in 1999.
Active Biotech AB
Box 724, S-220 07 Lund, Sweden
Tel +46 46-19 20 00
Fax +46 46 19 20 50